Sarepta Therapeutics | SRPT - Ordinary Share Capital


Sarepta Therapeutics reported $107.23M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Agios Pharmaceuticals USD 59.6M 264K Jun/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amgen USD 541M 0 Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Capricor Therapeutics USD 57.37M 11.65M Dec/2025
Daiichi Sankyo JPY 1.82B 1.68M Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Insmed USD 218.28M 1.76M Jun/2026
Ionis Pharmaceuticals USD 166.41M 773K Sep/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 1000K Sep/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Tectonic Therapeutic USD 19.24M 404.78K Jun/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026